Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
K.N. Chi, Shahneen Sandhu, Matthew R. Smith, Gerhardt Attard, Marniza Saad, David Olmos, Elena Castro, Guilhem Roubaud, Andrea Juliana Gomes, Eric J. Small, Dana E. Rathkopf, Howard Gurney, Wonho Jung, Gary Mason, Shiva Dibaj, Daphne Wu, B. Diorio, Karen A. Urtishak, A. del Corral, Peter Francis, W. Kim, Eleni Efstathiou (2023). Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. , 34(9), DOI: https://doi.org/10.1016/j.annonc.2023.06.009.
